DrugPatentWatch Database Preview

Details for Patent: 9,198,925

« Back to Dashboard

Which drugs does patent 9,198,925 protect, and when does it expire?

Patent 9,198,925 protects BYDUREON, BYDUREON PEN, XIGDUO XR, FARXIGA, and QTERN, and is included in four NDAs.

This patent has thirty-two patent family members in fifteen countries.

Summary for Patent: 9,198,925

Title:	Pharmaceutical formulations containing an SGLT2 inhibitor
Abstract:	Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate ##STR00001## and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
Inventor(s):	Bindra; Dilbir S. (New Brunswick, NJ), Dali; Mandar V. (Bridgewater, NJ), Parab; Prakash V. (New Brunswick, NJ), Patel; Jatin M. (New Brunswick, NJ), Tao; Li (New Brunswick, NJ), Tejwani; Ravindra W. (Monmouth Junction, NJ), Vatsaraj; Nipa (New Brunswick, NJ), Wu; Yongmei (New Brunswick, NJ)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	14/267,984
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,198,925

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		RX	Yes	Yes						TREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		RX	Yes	Yes						TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		RX	Yes	Yes						TREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		RX	Yes	Yes						TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE

Non-Orange Book US Patents Family Members for Patent 9,198,925

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,361,972	Pharmaceutical formulations containing an SGLT2 inhibitor
7,851,502	Pharmaceutical formulations containing an SGLT2 inhibitor
8,716,251	Pharmaceutical formulations containing an SGLT2 inhibitor
8,221,786	Pharmaceutical formulations containing an SGLT2 inhibitor

International Family Members for US Patent 9,198,925

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Japan	2010522244
China	102743340
Eurasian Patent Organization	200901277
Eurasian Patent Organization	020288